Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

Hard to believe, but there are still physicians out there who question the legitimacy of pharmacy compounding, so they’re reluctant to consider the compounded therapies you can provide their patients. That, or they press you to compound substances that are prohibited.

To help you educate prescribers, APC and the Pharmacy Compounding Foundation have developed two member-only briefing documents you can share with physicians and other prescribers. One is “The Truth About Pharmacy Compounding.” It explains the regulatory framework in which compounders operate and provides an overview of what can and cannot be compounded under federal law. The other is “Compounding Peptides: It’s Complicated.” It explains restrictions on peptide compounding as well as uncertainty surrounding the list of semaglutide on FDA’s Drug Shortage List.

The APC and PCF logos give credibility to the documents, and both are designed so you can add your pharmacy logo as well.

Download the new briefing papers here and share them with the physician offices you or your sales reps visit. (It’s an APC member-only tool, so you’ll need your login and password to access it.)